Day: March 9, 2023

NEWMARKET, Ontario, March 09, 2023 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced its unaudited fourth quarter and annual results. The Company will host a conference call and webcast to discuss the results today, March 9th at 10 a.m. ET, the details of which are further below. All dollar amounts are shown in thousands of United States dollars (“US $” or “$”), except per share amounts, unless otherwise noted. Recent HighlightsRecord sales and profitability for the Rubber Solutions segment; AirBoss Defense Group supported initial delivery of COVID test kits to the US Government; Adjusted EBITDA2 of $45.3 million (excluding the $57.0 million write-down of inventory) on Adjusted Profit2 of $12.6 million and a loss of $31.9 million; Finished...

– Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023 – Phase 1 dose escalation study of FHD-609, a selective degrader of BRD9, in synovial sarcoma continues to progress with initial safety and efficacy data expected mid-2023 – Advancing preclinical pipeline targeting key regulators of gene expression, including newly disclosed EP300 program, and selective BRM, ARID1B, CBP and other undisclosed programs, setting up the potential for six INDs over the next four years – Cash, cash equivalents and marketable securities of $345.8 million, as of December 31, 2022, provide cash runway into the second half of 2025 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics...

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones. “Our teams have done an outstanding job advancing SRF388 and SRF114, and we are pleased with the progress of both clinical programs,” said Rob Ross, M.D., chief executive...

IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501 expected in Q2 2023 in disease areas with 139 million agitation episodes,1-3*including Alzheimer’s-related agitation Positive data for BXCL701 in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) further validates Company’s AI drug discovery and development expertise; Company exploring strategic options for OnkosXcel subsidiary Company to host conference call at 8:30 a.m. ET today NEW HAVEN, Conn., March 09, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience...

MIAMI, March 09, 2023 (GLOBE NEWSWIRE) —  Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the fourth quarter and full year ended December 31, 2022. Unless otherwise noted, all results are presented in U.S. dollars. David Goubert, President & CEO of Ayr, said, “I’d like to thank our team for pulling together to deliver a strong fourth quarter, growing our adjusted EBITDA by 20% sequentially, and a second straight quarter of generating positive cash flow from operations. In the past few months, our team has begun the process of evaluating every aspect of our business with fresh eyes, conducting a thorough review of our markets, our people, and our processes, all in service seeking to maximize...

Canadian Cannabis Business Achieves Number Two Market Share Position Nationally and Maintained Number Two Position in First Two Months of 2023 Canadian Cannabis Retail Branded Sales Increased 25% Year-Over-Year, Significantly Outpacing Market Growth Commenced Cannabis Exports to Israel in Early January 2023 Fresh Produce Delivered Second Consecutive Quarter of Significant Sequential ImprovementVANCOUVER, British Columbia, March 09, 2023 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced its financial results for the fourth quarter and year ended December 31, 2022. All figures are in U.S. dollars unless otherwise indicated. Management Commentary “The fourth quarter of 2022 once again demonstrated the momentum in our Canadian Cannabis business as investments in...

HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular product revenues were roughly flat after adjusting for currency impacts. Pre-clinical revenue was down from prior year, with demand showing signs of recovery as ordering activity increased late in the quarter.      Jim Green, Chairman and CEO, concluded, “Looking to the future, I am excited about our pivot from cost optimization to profitable growth. We completed our previously announced portfolio optimization and...

Expanded clinical stage portfolio through licensing of U.S. rights to CLN-418 Received FDA clearance of IND application for CLN-978; submitted IND application for CLN-617 Initial clinical data updates for CLN-049 and CLN-619 on track for mid-2023 Potential for 6 clinical stage programs by year end and cash runway into 2026 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a year of remarkable execution at Cullinan Oncology, and the momentum with which we ended the year has continued into early 2023. With our partners at Taiho Oncology,...

Women’s Garden Collection Women’s Garden CollectionAKHG Swim Collection AKHG Swim CollectionFull Year Net Sales of $653.3 million Strong financial position with $250.0 million of liquidity Fourth quarter Net Sales of $241.8 million; diluted EPS of $0.23 MOUNT HOREB, Wisc., March 09, 2023 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s casual wear, workwear and accessories, today announced its financial results for the fiscal fourth quarter and fiscal year ended January 29, 2023. Highlights for the Fourth Quarter Ended January 29, 2023Net sales of $241.8 million compared to $270.8 million in the prior-year fourth quarter Strategic investment in a new automated Southeast fulfillment center that is on time and...